FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

Yang Lu

doi:10.1097/RLU.0000000000002408

FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

Yang Lu

Research output: Contribution to journal › Article › peer-review

14 Scopus citations

Abstract

An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT.

Original language	English (US)
Pages (from-to)	167-168
Number of pages	2
Journal	Clinical nuclear medicine
Volume	44
Issue number	2
DOIs	https://doi.org/10.1097/RLU.0000000000002408
State	Published - Feb 1 2019

Keywords

FDG PET/CT
immunotherapy
melanoma
pembrolizumab
sarcoidosis

ASJC Scopus subject areas

Radiology Nuclear Medicine and imaging

Access to Document

10.1097/RLU.0000000000002408

Cite this

@article{e97a23b81d924f409970b7a46fa6acb9,

title = "FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis",

abstract = "An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT.",

keywords = "FDG PET/CT, immunotherapy, melanoma, pembrolizumab, sarcoidosis",

author = "Yang Lu",

year = "2019",

month = feb,

day = "1",

doi = "10.1097/RLU.0000000000002408",

language = "English (US)",

volume = "44",

pages = "167--168",

journal = "Clinical nuclear medicine",

issn = "0363-9762",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

AU - Lu, Yang

PY - 2019/2/1

Y1 - 2019/2/1

N2 - An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT.

AB - An 80-year-old man with metastatic melanoma had been receiving treatment with pembrolizumab from September 2015 until June 2017. Series FDG PET/CT scans from March 7, 2017, to June 14, 2018, showed the course of biopsy-proven pembrolizumab-induced sarcoidosis. Reported here is the first case of multiorgan sarcoidosis induced by pembrolizumab and its self-resolving course on FDG PET/CT.

KW - FDG PET/CT

KW - immunotherapy

KW - melanoma

KW - pembrolizumab

KW - sarcoidosis

UR - http://www.scopus.com/inward/record.url?scp=85059493158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059493158&partnerID=8YFLogxK

U2 - 10.1097/RLU.0000000000002408

DO - 10.1097/RLU.0000000000002408

M3 - Article

C2 - 30516667

AN - SCOPUS:85059493158

SN - 0363-9762

VL - 44

SP - 167

EP - 168

JO - Clinical nuclear medicine

JF - Clinical nuclear medicine

IS - 2

ER -

FDG PET/CT Course of Pembrolizumab-Associated Multiorgan Sarcoidosis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this